Pharmaceuticals

Key Developments and Trends Steering the Peanut Allergy Treatment Market Forward: Advancements In Peanut Allergy Treatment Focuses On Anti-IgE Monoclonal Antibodies

August 22, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Fast Is The Peanut Allergy Treatment Market Expected to Grow Between 2025 And 2029?#_x000D_

The market for peanut allergy treatment has seen a swift expansion in the recent past. The market, which was valued at $0.45 billion in 2024, is projected to reach $0.5 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.4%. The key drivers propelling the market growth during the historic period include a rise in incidence rates, advancements in diagnostic methods, increased public consciousness and apprehension, the progression of early intervention tactics, and the approval of regulatory bodies for the treatment of peanut allergies._x000D_

_x000D_

The market for peanut allergy treatment is anticipated to experience a swift expansion in the coming years, reaching $0.74 billion by 2029 with a CAGR of 10.2%. This growth during the anticipated period can be attributed to factors such as the persistent increase in prevalence, the progression of tailored medicine strategies, the emergence of new immunotherapy procedures, and a surge in both public and private funding, not forgetting the development of telemedicine services. The forecast period also expects trends like the amplified use of immunotherapy, breakthroughs in biologic treatments, the incorporation of probiotic-centric treatments, technological advancements in delivery systems, focused medical approaches, and acceptance and support from regulators._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp_x000D_

_x000D_

#How Are Key Drivers in the Industry Acting as Catalysts for the Growth of thePeanut Allergy Treatment Market?#_x000D_

The increase in research and development expenditure into allergy solutions is a major catalyst for the expansion of the peanut allergy treatment market. Research and development (R&D) funds, which are financial resources committed by corporations, institutions or governments, are intended to spur innovation, product enhancement, and technological progress. The funding into research and development for allergy solutions is vital for the evolution of peanut allergy therapies. This financial backing stimulates the inception of breakthrough immunotherapies and tolerance-inducing methods aimed towards lowering allergic responses and enhancing the life quality of individuals affected by peanut allergies. For instance, Aravax, an Australian clinical-stage biotechnology company, received a strategic investment of $12 million from the Victorian Government in January 2024, aiming to significantly push forward the global peanut allergy treatment. This investment is a component of a larger $66 million round, aiming to develop Aravax’s pioneering immunotherapy, PVX108. This endeavor has successfully obtained Phase 2 trial accreditations from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), highlighting its potential to impact public health on a global scale. Therefore, the funding into research and development of allergy solutions is propelling the expansion of the peanut allergy treatment market._x000D_

_x000D_

#Which Segments in the Peanut Allergy Treatment Offer the Most Growth?#_x000D_

The peanut allergy treatment market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes_x000D_

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration_x000D_

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines_x000D_

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)_x000D_

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers_x000D_

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15888&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of thePeanut Allergy Treatment Market?# Market?#_x000D_

North America was the largest region in the peanut allergy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#What Are the Current Market Growth and Trends in the Peanut Allergy Treatment Industry?#_x000D_

Leading corporations in the peanut allergy treatment market, like Novartis Pharmaceuticals Corporation, are honing in on the development of more precise, biologic therapies like anti-IgE monoclonal antibodies; this is intended to offer more effective solutions for managing peanut allergies. This approach ultimately aims to greatly improve patient outcomes as well as their quality of life. Anti-IgE monoclonal antibodies are a specific type of therapeutic agent that aims to target and neutralize immunoglobulin E (IgE) antibodies in the body. As an example, in February 2024, Switzerland’s Novartis Pharmaceuticals Corporation’s drug – Xolair (omalizumab), received FDA approval for patients aged 1 year and above with IgE-mediated food allergies to mitigate allergic reactions including anaphylaxis. This major decision was taken based on the results of the NIH-sponsored Phase III OUtMATCH study, which revealed a substantial enhancement in food allergy tolerance in patients who were treated with Xolair, compared to patients who received a placebo._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Peanut Allergy Treatment Market?#_x000D_

Peanut allergy treatment refers to various medical approaches designed to manage and reduce the severity of allergic reactions to peanuts. These treatments involve various approaches, such as epicutaneous immunotherapy and biologic therapies aimed at desensitizing individuals to peanuts and mitigating allergic reactions._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15888_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_